Monoclonal antibody successes in the clinic (original) (raw)

Nature Biotechnology volume 23, pages 1073–1078 (2005)Cite this article

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819–822 (2001).
    Article CAS PubMed Google Scholar
  2. Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110–118 (2002).
    CAS PubMed Google Scholar
  3. Reichert, J. & Pavolu, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3, 383–384 (2004).
    Article CAS PubMed Google Scholar
  4. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
    Article CAS PubMed Google Scholar
  5. Milstein, C. The hybridoma revolution: an offshoot of basic research. Bioessays 21, 966–973 (1999).
    Article CAS PubMed Google Scholar
  6. Morrison, S.L. et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).
    Article CAS PubMed PubMed Central Google Scholar
  7. Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).
    Article CAS PubMed Google Scholar
  8. Cole, S.P., Campling, B.G., Atlaw, T., Kozbor, D. & Roder, J.C. Human monoclonal antibodies. Mol. Cell. Biochem. 62, 109–120 (1984).
    Article CAS PubMed Google Scholar
  9. Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).
    Article CAS PubMed Google Scholar
  10. Pasqualini, R. & Arap, W. Hybridoma-free generation of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 101, 257–259 (2004).
    Article CAS PubMed Google Scholar
  11. Inglis, T.J.J. et al. Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341, 303 (1993).
    Article CAS PubMed Google Scholar
  12. Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
    Article CAS PubMed Google Scholar
  13. Fleming, T. (ed.). Red Book (Thomson PDR, Montvale, New Jersey, 2004).
    Google Scholar
  14. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

The authors gratefully acknowledge the assistance of the companies that provided survey data. We also thank H. Pujar for reviewing the manuscript and for providing helpful comments and suggestions.

Author information

Authors and Affiliations

  1. Tufts University Center for the Study of Drug Development (CSDD), 192 South Street, Suite 550, Boston, 02111, Massachusetts, USA
    Janice M Reichert, Clark J Rosensweig, Laura B Faden & Matthew C Dewitz

Author notes

  1. Clark J. Rosensweig and Matthew C. Dewitz were summer interns at CSDD.

Authors

  1. Janice M Reichert
    You can also search for this author inPubMed Google Scholar
  2. Clark J Rosensweig
    You can also search for this author inPubMed Google Scholar
  3. Laura B Faden
    You can also search for this author inPubMed Google Scholar
  4. Matthew C Dewitz
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Reichert, J., Rosensweig, C., Faden, L. et al. Monoclonal antibody successes in the clinic.Nat Biotechnol 23, 1073–1078 (2005). https://doi.org/10.1038/nbt0905-1073

Download citation

This article is cited by